These clinical reports suggest that GM and its metabolites may be significantly associated with T2D progression [153], and GLP-1R and FXR agonists have been proposed as a viable pharmaceutical strategy for treating diet-induced T2D. This evidence concerns the gene NR1H4 and type 2 diabetes mellitus.